Randstad Japan Names PPD-SNBL a Top-Five Growth Business and Desirable Employer

In recognizing PPD-SNBL’s rapid growth, Randstad Japan, a subsidiary of Randstad N.V., a global leader in the human resources services industry, commended PPD-SNBL for its success with staff growth and retention. The recognition, announced in its Growing Companies Research 2019, is based on a survey of more than 7,000 respondents in the Tokyo metropolitan area conducted by a third-party research organization.

“Our joint venture, coupling PPD’s global capabilities with SNBL’s depth of clinical knowledge and scope within Japan, has catapulted us to the forefront of the CRO industry in the country, and enabled us to attract and retain exceptional talent,” said Sebastian Pacios, M.D., senior vice president, clinical development.

Toshihiko Seki, chief financial officer of PPD-SNBL, said, “Our success results from three factors: holding employee turnover to 4-7 percent since the joint venture’s formation; continuing to grow our workforce every year; and placing strong emphasis on the Japanese philosophy that treating employees as a family is the core of bonding a workforce. We are excited about this recognition by Randstad and look forward to our continued success.”

PPD-SNBL’s recognition by Randstad was based on an evaluation of multiple criteria, the most important being the continuous growth of employee headcount through recruitment and retention.

“PPD-SNBL was able to accomplish this over the past several years in the difficult Japanese recruiting market,” said Goro Nakayama, chief marketing officer of Randstad Japan.

With offices in Tokyo, Osaka and Kagoshima, PPD-SNBL brings together PPD’s global resources and clinical trial expertise with SNBL’s nearly 20-year history and in-depth knowledge of providing clinical development services in Japan.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 48 countries and more than 21,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.

About SNBL

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a Japanese global business that works in pre-clinical research, clinical pharmacology research, pharmacokinetics and analysis, and translational research. SNBL has over 1,700 employees in Japan, North America, Europe and other parts of Asia. Since being founded as Japan’s first contract research organization in 1957, SNBL has supported clients by committing to freeing patients from suffering by supporting drug development and improving medical technology. SNBL is a listed company on the first section of the Tokyo Stock Exchange. For more information, visit https://www.snbljapan.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190619005432/en/